Unlearn.AI

Overview

Unlearn.AI is a leading artificial intelligence company dedicated to accelerating drug development by enabling smaller, faster clinical trials. The company leverages advanced machine learning and causal inference techniques to create 'digital twins' – comprehensive, realistic simulations of individual patients based on historical clinical trial data.

By generating a pool of digital twins for potential control arm patients, Unlearn.AI allows researchers to supplement or replace traditional control groups in randomized clinical trials. This approach can significantly reduce the number of patients required for a trial, decrease study duration, and potentially lower costs. Their technology focuses on generating credible, statistically robust evidence compatible with regulatory requirements, aiming to bring novel therapies to patients faster.

Key Features

• AI-powered generation of patient digital twins
• Creation of synthetic control arms for clinical trials
• Reduction in required patient enrollment numbers
• Acceleration of clinical trial timelines
• Increased statistical power in trials
• Bayesian statistical methods for enhanced analysis
• Focus on regulatory credibility and evidence generation
• Applies to various therapeutic areas

Supported Platforms

• Web Browser